Biotron Limited (BIT.AX)
AUD 0.02
(-5.88%)
AUD 0.02
(-5.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -386.06 Thousand AUD | 90.2% |
| 2023 | -3.93 Million AUD | -136.7% |
| 2022 | -1.66 Million AUD | 60.42% |
| 2021 | -4.2 Million AUD | 44.8% |
| 2020 | -7.61 Million AUD | -32.7% |
| 2019 | -5.73 Million AUD | -271.99% |
| 2018 | -1.54 Million AUD | 22.36% |
| 2017 | -1.98 Million AUD | 41.86% |
| 2016 | -3.41 Million AUD | 24.42% |
| 2015 | -4.52 Million AUD | -156.39% |
| 2014 | -1.76 Million AUD | 63.19% |
| 2013 | -4.79 Million AUD | 39.27% |
| 2012 | -7.89 Million AUD | -267.94% |
| 2011 | -2.14 Million AUD | -20.46% |
| 2010 | -1.78 Million AUD | -87.31% |
| 2009 | -950.58 Thousand AUD | 53.94% |
| 2008 | -2.06 Million AUD | -49.67% |
| 2007 | -1.37 Million AUD | 70.18% |
| 2006 | -4.62 Million AUD | -118.84% |
| 2005 | -2.11 Million AUD | 19.29% |
| 2004 | -2.61 Million AUD | 51.3% |
| 2003 | -5.37 Million AUD | 29.07% |
| 2002 | -7.57 Million AUD | 21.98% |
| 2001 | -9.71 Million AUD | 11.87% |
| 2000 | -11.02 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -386.06 Thousand AUD | 90.2% |
| 2024 Q2 | -693.63 Thousand AUD | 0.0% |
| 2024 Q4 | -386.06 Thousand AUD | 0.0% |
| 2023 Q4 | -3.93 Million AUD | 0.0% |
| 2023 Q2 | -6.4 Million AUD | 0.0% |
| 2023 FY | -3.93 Million AUD | -136.7% |
| 2022 Q4 | -1.66 Million AUD | 0.0% |
| 2022 Q2 | -2.25 Million AUD | 0.0% |
| 2022 FY | -1.66 Million AUD | 60.42% |
| 2021 FY | -4.2 Million AUD | 44.8% |
| 2021 Q4 | -4.2 Million AUD | 0.0% |
| 2021 Q2 | -5.12 Million AUD | 0.0% |
| 2020 Q4 | -7.61 Million AUD | 0.0% |
| 2020 FY | -7.61 Million AUD | -32.7% |
| 2020 Q2 | -8.61 Million AUD | 0.0% |
| 2019 Q2 | -6.99 Million AUD | 0.0% |
| 2019 Q4 | -5.73 Million AUD | 0.0% |
| 2019 FY | -5.73 Million AUD | -271.99% |
| 2018 Q2 | -1.55 Million AUD | 0.0% |
| 2018 FY | -1.54 Million AUD | 22.36% |
| 2018 Q4 | -1.54 Million AUD | 0.0% |
| 2017 Q4 | -1.98 Million AUD | 0.0% |
| 2017 FY | -1.98 Million AUD | 41.86% |
| 2017 Q2 | -1.42 Million AUD | 0.0% |
| 2016 Q4 | -3.41 Million AUD | 0.0% |
| 2016 FY | -3.41 Million AUD | 24.42% |
| 2016 Q2 | -3.57 Million AUD | 0.0% |
| 2015 FY | -4.52 Million AUD | -156.39% |
| 2015 Q4 | -4.52 Million AUD | 0.0% |
| 2015 Q2 | -3.06 Million AUD | 0.0% |
| 2014 Q2 | -2.14 Million AUD | 0.0% |
| 2014 FY | -1.76 Million AUD | 63.19% |
| 2014 Q4 | -1.76 Million AUD | 0.0% |
| 2013 Q3 | -4.79 Million AUD | 23.95% |
| 2013 Q2 | -6.3 Million AUD | 0.0% |
| 2013 FY | -4.79 Million AUD | 39.27% |
| 2013 Q1 | -6.3 Million AUD | 20.15% |
| 2013 Q4 | -4.79 Million AUD | 0.0% |
| 2012 Q4 | -7.89 Million AUD | 0.0% |
| 2012 FY | -7.89 Million AUD | -267.94% |
| 2011 FY | -2.14 Million AUD | -20.46% |
| 2011 Q4 | -2.14 Million AUD | 0.0% |
| 2010 FY | -1.78 Million AUD | -87.31% |
| 2010 Q4 | -1.78 Million AUD | 0.0% |
| 2009 Q4 | -950.58 Thousand AUD | 0.0% |
| 2009 FY | -950.58 Thousand AUD | 53.94% |
| 2008 Q4 | -2.06 Million AUD | 0.0% |
| 2008 FY | -2.06 Million AUD | -49.67% |
| 2007 Q4 | -1.37 Million AUD | 0.0% |
| 2007 FY | -1.37 Million AUD | 70.18% |
| 2006 FY | -4.62 Million AUD | -118.84% |
| 2006 Q4 | -4.62 Million AUD | 0.0% |
| 2005 FY | -2.11 Million AUD | 19.29% |
| 2005 Q4 | -2.11 Million AUD | 0.0% |
| 2004 Q4 | -2.61 Million AUD | 0.0% |
| 2004 FY | -2.61 Million AUD | 51.3% |
| 2003 FY | -5.37 Million AUD | 29.07% |
| 2003 Q4 | -5.37 Million AUD | 0.0% |
| 2002 FY | -7.57 Million AUD | 21.98% |
| 2002 Q4 | -7.57 Million AUD | 0.0% |
| 2001 FY | -9.71 Million AUD | 11.87% |
| 2001 Q4 | -9.71 Million AUD | 0.0% |
| 2000 FY | -11.02 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 97.957% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 60.69% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 107.619% |
| Biome Australia Limited | -1.56 Million AUD | 75.297% |
| Patrys Limited | -2.24 Million AUD | 82.77% |
| Orthocell Limited | -19.92 Million AUD | 98.062% |
| Imugene Limited | -91.56 Million AUD | 99.578% |
| Noxopharm Limited | -2.31 Million AUD | 83.359% |
| PYC Therapeutics Limited | -65.76 Million AUD | 99.413% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 87.354% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 96.201% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 93.895% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 93.779% |
| CSL Limited | 15.76 Billion AUD | 100.002% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 96.964% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | 45.59% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 99.789% |
| Starpharma Holdings Limited | -19.83 Million AUD | 98.053% |
| Nanollose Limited | -96.22 Thousand AUD | -301.214% |
| Memphasys Limited | 4.13 Million AUD | 109.336% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 93.592% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 92.207% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 78.829% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 99.513% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 68.825% |
| Race Oncology Limited | -17.18 Million AUD | 97.754% |
| Nyrada Inc. | -4.76 Million AUD | 91.905% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 99.635% |
| Dimerix Limited | -21.99 Million AUD | 98.244% |
| PharmAust Limited | -9.71 Million AUD | 96.026% |
| Immutep Limited | -122.18 Million AUD | 99.684% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 99.717% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 96.906% |
| BTC Health Limited | -2.02 Million AUD | 80.908% |
| Acrux Limited | -1.45 Million AUD | 73.521% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 97.741% |
| Tissue Repair Ltd | -16.44 Million AUD | 97.652% |
| AdAlta Limited | -845.17 Thousand AUD | 54.321% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 97.922% |
| Hexima Limited | -2.22 Million AUD | 82.658% |
| AnteoTech Limited | -5 Million AUD | 92.281% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 97.804% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 88.632% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 92.756% |
| Actinogen Medical Limited | -9.13 Million AUD | 95.772% |
| Immuron Limited | -11.48 Million AUD | 96.638% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 97.574% |